Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Vancomycin Dosing with PPK Models
NCT05964114Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Open-label, single-arm trial of vancomycin in bacterial infection, sponsored by Erasmus MC. Primary endpoint: Number of patients within target range of vancomycin for standard treatment versus treatment using MIPD within the first three days of treatment at 3 days. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
vancomycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05964114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05964114.